Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-02-16FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved an original application for a generic mixed amphetamine salts product (dextroamphetamine and amphetamine salts) from Amneal Pha…
-
FDA approval · 2016-02-09FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate from Sandoz Inc, resulting in an expanded/updated authorization for the product.
-
FDA approval · 2016-01-27FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Original Application (Neos Therapeutics, LP)
FDA approved AMPHETAMINE EXTENDED-RELEASE under an original NDA for the treatment of attention-deficit/hyperactivity disorder.
-
FDA approval · 2015-12-28FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for a generic dexmethylphenidate hydrochloride product from Amneal Pharmaceuticals of New York L…
-
FDA approval · 2015-12-21FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved an original ANDA for dexmethylphenidate hydrochloride from Amneal Pharmaceuticals of New York LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-12-04FDA Approved: QUILLICHEW ER — Original Application (NextWave Pharmaceuticals, Inc)
FDA approved QUILLICHEW ER (methylphenidate hydrochloride) through an original NDA submitted by NextWave Pharmaceuticals, Inc.
-
FDA approval · 2015-12-04FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) from Sandoz Inc.
-
FDA approval · 2015-12-04FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-12-04FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (KVK-TECH, INC)
FDA approves the original application for dexmethylphenidate hydrochloride tablets from KVK-Tech, Inc., establishing its use as a generic tr…
-
FDA approval · 2015-12-04FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' original application for a generic dexmethylphenidate hydrochloride product intended for ADHD.
-
FDA approval · 2015-11-23FDA Approved: DEXTROAMPHETAMINE SULFATE — Original Application (KVK-Tech, Inc.)
FDA approved a generic version of dextroamphetamine sulfate under an Original Application for KVK-Tech, Inc., making this product available …
-
FDA approval · 2015-11-17FDA Approved: METHAMPHETAMINE HYDROCHLORIDE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s generic methamphetamine hydrochloride tablets under an original ANDA; indications include atte…
-
FDA approval · 2015-11-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals,Inc.)
FDA approved Lupin Pharmaceuticals' generic methylphenidate hydrochloride product via Original Application, making a generic version of meth…
-
FDA approval · 2015-11-09FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
The FDA approved a supplemental NDA for the Methylphenidate Transdermal System (methylphenidate) from PADAGIS US LLC, enabling a new transde…
-
FDA approval · 2015-10-23FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Teva’s generic product containing four amphetamine salt components (dextroamphetamine saccha…
-
FDA approval · 2015-10-19FDA Approved: DYANAVEL XR — Original Application (NextWave Pharmaceuticals, Inc)
FDA approved DYANAVEL XR (amphetamine extended-release) from NextWave Pharmaceuticals as a new treatment for attention-deficit/hyperactivity…
-
FDA approval · 2015-09-29FDA Approved: METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Original Application (SpecGx LLC)
FDA approved a methylphenidate hydrochloride extended-release generic from SpecGx LLC under an Original Application (ANDA).
-
FDA approval · 2015-09-24FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' dexmethylphenidate hydrochloride as an original generic product for the treatment of attention-d…
-
FDA approval · 2015-09-22FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Camber Pharmaceutical Inc)
The FDA approved Camber Pharmaceutical's methylphenidate hydrochloride as an Original Application, providing a generic version of the stimul…
-
FDA approval · 2015-09-15FDA Approved: APTENSIO XR — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for Aptensio XR (methylphenidate hydrochloride) by Rhodes Pharmaceuticals L.P., resulting in a label…
-
FDA approval · 2015-08-25FDA Approved: ATOMOXETINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for a generic atomoxetine product by Zydus Pharmaceuticals USA Inc. The product is indicated for the…
-
FDA approval · 2015-08-20FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Actavis's generic dextroamphetamine/amphetamine salt product. The approval updates labeling and …
-
FDA approval · 2015-08-14FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System by PADAGIS US LLC.
-
FDA approval · 2015-08-14FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals,Inc.)
FDA approved Lupin Pharmaceuticals' methylphenidate hydrochloride generic under an Original Application (ANDA 204602); this provides a gener…
-
FDA approval · 2015-08-13FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for dexmethylphenidate hydrochloride from Teva Pharmaceuticals USA, Inc., signaling an addition …